{
    "eid": "2-s2.0-85115451536",
    "title": "Prevalence and risk of residual viremia after ART in low- and middle-income countries A cross-sectional study",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "HIV molecular and monitoring core gag single copy assay",
        "HIV-1",
        "lowand middle-income countries",
        "prevalence",
        "residual viremia",
        "risk factors"
    ],
    "authors": [
        "Sivaporn Gatechompol",
        "Lu Zheng",
        "Yajing Bao",
        "Anchalee Avihingsanon",
        "Stephen J. Kerr",
        "Nagalingeswaran Kumarasamy",
        "James G. Hakim",
        "Frank Maldarelli",
        "Robert J. Gorelick",
        "Jorden L. Welker",
        "Jeffrey D. Lifson",
        "Mina C. Hosseinipour",
        "Joseph J. Eron",
        "Kiat Ruxrungtham"
    ],
    "citedby-count": 1,
    "ref-count": 55,
    "ref-list": [
        "HIV persists throughout deep tissues with repopulation from multiple anatomical sources",
        "HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation",
        "Recovery of replication-competent HIV despite prolonged suppression of plasma viremia",
        "Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy",
        "Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy",
        "Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy",
        "Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection",
        "Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study",
        "Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens",
        "Viral load differences in early infection with two HIV-1 subtypes",
        "HIV-1 subtype as a determinant of disease progression",
        "Combinatorial latency reactivation for HIV-1 subtypes and variants",
        "New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond",
        "New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma",
        "The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial",
        "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings",
        "Antiretroviral therapies in women after single-dose nevirapine exposure",
        "Immune activation and HIV persistence: considerations for novel therapeutic interventions",
        "Serum immune activation markers are persistently increased in patients with HIV infection after 6years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells",
        "Potential implication of residual viremia in patients on effective antiretroviral therapy",
        "HIV-1 very low level viremia is associated with virological failure in highly active antiretroviral treatment-treated patients",
        "Continued slow decay of the residual plasma viremia level in HIV-1-infected adults receiving long-term antiretroviral therapy",
        "ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia",
        "Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: their dynamic decay and correlations with immunological parameters and virological success",
        "Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?",
        "Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy",
        "Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine",
        "Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation",
        "The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation",
        "Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy",
        "The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial",
        "Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy",
        "HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects",
        "Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy",
        "Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life",
        "Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy",
        "The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial",
        "HIV rebounds from latently infected cells, rather than from continuing low-level replication",
        "Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy",
        "Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells",
        "Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy",
        "Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure",
        "Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination antiretroviral therapy",
        "Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance",
        "Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice",
        "Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA",
        "Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen",
        "Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA",
        "A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response",
        "Sex-based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation",
        "HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda",
        "Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction",
        "Brief report: pulmonary tuberculosis is associated with persistent systemic inflammation and decreased HIV-1 reservoir markers in coinfected Ugandans",
        "Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts",
        "The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Reston",
            "@id": "60109509",
            "affilname": "Leidos Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60109509",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lilongwe",
            "@id": "60072681",
            "affilname": "UNC Project-Malawi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60072681",
            "affiliation-country": "Malawi"
        },
        {
            "affiliation-city": "Chennai",
            "@id": "60072222",
            "affilname": "VHS Medical Centre India",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60072222",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Harare",
            "@id": "60033774",
            "affilname": "University of Zimbabwe",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033774",
            "affiliation-country": "Zimbabwe"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chapel Hill",
            "@id": "60025111",
            "affilname": "The University of North Carolina at Chapel Hill",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025111",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "TRC-ARC",
        "National Institutes of Health",
        "National Cancer Institute",
        "National Institute of Allergy and Infectious Diseases",
        "AIDS Clinical Trials Group",
        "CTU"
    ]
}